The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | The benefits of standardized patient-reported outcomes in lung cancer trials
Alberto Servetto, MD, PhD, University of Naples Federico II, Naples, Italy, discusses the clinical significance of the PRO4All project, which aims to define lung cancer-specific patient-reported outcome measures (PROMs) used in clinical trials. The project was conducted across multiple institutions across Italy, and a more standardized methodology in measuring patient-reported outcomes will benefit clinical trials and patients. The findings can even also be translated into clinical practice. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
